T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dollar General
DG
|
+$1.37B |
| 2 |
Intel
INTC
|
+$1.28B |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$1B |
| 4 |
Nike
NKE
|
+$859M |
| 5 |
Uber
UBER
|
+$825M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.67B |
| 2 |
Amazon
AMZN
|
+$2.15B |
| 3 |
NVIDIA
NVDA
|
+$1.64B |
| 4 |
Humana
HUM
|
+$1.57B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$1.33B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.09% |
| 2 | Healthcare | 15.81% |
| 3 | Financials | 11.13% |
| 4 | Consumer Discretionary | 10.82% |
| 5 | Communication Services | 8.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1051
BorgWarner
BWA
$12.4B
| $12.5M | ﹤0.01% |
348,832
+5,615
| +2% | +$200K |
|
1052
Hormel Foods
HRL
$11B
| $12.4M | ﹤0.01% |
387,237
+1
| +0% | +$33 |
|
1053
NCR Voyix
VYX
$943M
| $12.4M | ﹤0.01% |
730,779
-825,167
| -53% | -$13.2M |
|
1054
Palomar
PLMR
$3.24B
| $12.2M | ﹤0.01% |
219,068
-119,165
| -35% | -$6.67M |
|
1055
Extreme Networks
EXTR
$2.78B
| $12.2M | ﹤0.01% |
688,748
-326,706
| -32% | -$6.18M |
|
1056
BWX Technologies
BWXT
$12.3B
| $12.1M | ﹤0.01% |
158,254
-6,246
| -4% | -$480K |
|
1057
United Parks & Resorts
PRKS
$1.45B
| $12.1M | ﹤0.01% |
228,852
-2,532
| -1% | -$121K |
|
1058
Cabaletta Bio
CABA
$339M
| $12M | ﹤0.01% |
527,765
+512,450
| +3,346% | +$8.62M |
|
1059
First Citizens BancShares
FCNCA
$23.7B
| $11.9M | ﹤0.01% |
8,404
+2,209
| +36% | +$3.1M |
|
1060
American Airlines Group
AAL
$8.95B
| $11.9M | ﹤0.01% |
866,648
+3,520
| +0.4% | +$44.2K |
|
1061
CI&T Inc
CINT
$370M
| $11.8M | ﹤0.01% |
2,239,515
-40,372
| -2% | -$212K |
|
1062
Darling Ingredients
DAR
$9.56B
| $11.7M | ﹤0.01% |
235,408
-3,143,413
| -93% | -$143M |
|
1063
Tapestry
TPR
$22.6B
| $11.7M | ﹤0.01% |
318,625
-7
| -0% | -$215 |
|
1064
Exponent
EXPO
$3.06B
| $11.7M | ﹤0.01% |
133,069
-165,578
| -55% | -$13.6M |
|
1065
Axsome Therapeutics
AXSM
$10.2B
| $11.7M | ﹤0.01% |
146,557
+123,949
| +548% | +$8.29M |
|
1066
Omnicell
OMCL
$1.54B
| $11.6M | ﹤0.01% |
307,222
-3,676
| -1% | -$135K |
|
1067
Campbell Soup
CPB
$5.98B
| $11.5M | ﹤0.01% |
265,823
+9,702
| +4% | +$399K |
|
|
GBIO
1068
DELISTED
Generation Bio
GBIO
| $11.4M | ﹤0.01% |
692,617
-52,853
| -7% | -$922K |
|
1069
Cadre Holdings
CDRE
$1.12B
| $11.4M | ﹤0.01% |
346,778
+28,390
| +9% | +$859K |
|
1070
Markel Group
MKL
$21.6B
| $11.3M | ﹤0.01% |
7,977
+373
| +5% | +$529K |
|
1071
Novartis
NVS
$279B
| $11.3M | ﹤0.01% |
112,153
-1,261
| -1% | -$122K |
|
1072
Enovis
ENOV
$1.05B
| $11.3M | ﹤0.01% |
201,842
+172,468
| +587% | +$8.6M |
|
1073
Immunome
IMNM
$2.46B
| $11.2M | ﹤0.01% |
1,051,222
+877,592
| +505% | +$7.3M |
|
1074
Franklin Templeton
BEN
$16.6B
| $11.2M | ﹤0.01% |
377,304
-503
| -0.1% | -$12.5K |
|
1075
Valmont Industries
VMI
$9.03B
| $11.1M | ﹤0.01% |
47,502
+390
| +0.8% | +$85.7K |
|
Similar funds
T. Rowe Price Associates's Q4 2023 Portfolio in Review
As of Q4 2023, T. Rowe Price Associates held 2,974 positions worth $744B, up 9.1% from $682B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates's Q4 2023 filing shows 92 new, 1,834 increased, 805 reduced and 67 closed positions. Its largest new stake was Canadian Natural Resources: 6,473,658 shares worth $212M. The largest sale was Microsoft, an estimated $2.67B.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 30% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q4 2023 buy was Canadian Natural Resources: 6,473,658 shares worth $212M.
- T. Rowe Price Associates added most to Dollar General in Q4 2023, an estimated $1.37B increase.
- T. Rowe Price Associates's biggest Q4 2023 reduction was Microsoft, cutting an estimated $2.67B.
- T. Rowe Price Associates fully exited Activision Blizzard in Q4 2023, selling an estimated $293M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $744B portfolio in Q4 2023.
- T. Rowe Price Associates opened 92 new positions and closed 67 in Q4 2023.
- T. Rowe Price Associates's portfolio value rose 9.1% quarter-over-quarter to $744B.
Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.